logo
A man had heart attack symptoms on a flight. A cardiologist and a pocket-sized tool on board may have helped save his life

A man had heart attack symptoms on a flight. A cardiologist and a pocket-sized tool on board may have helped save his life

Yahoo18-05-2025
Oklahoma cardiologist Dr. TJ Trad was fast asleep on his flight from Uganda last month when a member of his team woke him up to say someone needed a doctor.
Trad rushed over to the passenger who needed help to find a man drenched with sweat and complaining of chest pain. The man looked at the doctor and anxiously asked, 'am I going to die?'
'Not today,' Trad told the man.
He believed that the man in front of him was having a heart attack – pain the doctor was intimately familiar with after surviving one just last year.
Trad also knew he had the tools that might help save the man's life if it was a heart attack: medication and medical devices he had on him because he was flying home from a medical mission trip in Uganda with Cura for the World – an organization he founded that builds clinics in areas of need.
He also had a pocket-sized electrocardiogram, or ECG – something he never leaves home without after his own heart attack. The device, about the size of a credit card, would be a crucial tool in understanding the man's symptoms.
Now he just had to get to work.
It was three hours into the April 29 KLM flight to Amsterdam when Trad was thrust into emergency response mode.
The patient said that on a scale of one to 10, his chest pain was at a 10.
'Do we land right now?' Trad recalled the man's wife nervously asking.
Trad realized the first step was to calm down the Dutch couple, nearby passengers and flight crew.
'I think our training is so extensive that you almost get trained to be the captain of the ship and to calm everyone around you,' he said.
Trad then created a makeshift emergency room across a row of airplane seats, laid the man down with airplane pillows and propped his feet up to bring blood back to his heart.
After ruling out blood sugar and blood clot complications, the doctor used a 12-lead ECG from the medical mission trip to assess whether the man was having a heart attack. He quickly gave him five medications typically used to treat heart attacks.
Trad then used his personal ECG – an electrocardiogram that measures the heart's electrical activity – to help monitor the man's heart for abnormal beats, or arrhythmias. Trad has kept the device, a KardiaMobile card, in his wallet ever since his heart attack last year in case he has another cardiac event.
'The later manifestation of a heart attack is an arrhythmia. That's how people die,' Trad explained.
Although the 12-lead ECG was crucial to confirm the man was showing symptoms of a heart attack, the doctor said the card allowed him to continually monitor for arrhythmias in the three hours that followed.
The man put his thumbs on the card, and it transmitted data on his heart activity to Trad's app via Bluetooth.
Within 45 minutes after he took the medication, the man's chest pain and heart rate started to get better, the doctor said.
Trad's own heart attack had prevented him from going on his medical mission trip to Uganda in February 2024, leading him to go on a make-up trip that put him on the same plane as the man he helped save.
The doctor said his heart attack led to him being in the right place at the right time.
'I believe everything happens for a reason, I truly do,' he said.
During the ordeal, the pilot asked if they should divert the flight to Tunisia after speaking with the KLM on-ground physician, but Trad assured the crew that the patient was stable enough to make it to Amsterdam.
'We had a nurse that was taking his vitals every 10 to 15 minutes… and we had him hooked up to all these things… if we would have landed in Tunisia, they wouldn't have done anything differently other than obviously taking him to get a heart cath,' Trad said, referring to the catheterization procedure that allows doctors to examine or treat the heart and coronary arteries.
The man was stable throughout the remaining two hours of the flight. His chest pain returned as the plane was about to land, but additional medication resolved it, Trad said.
The man's wife told CNN that Trad and a nurse helped prevent her husband's condition from getting worse and did an 'unforgettable job.'
Once they landed, the man thanked the doctor and his wife hugged him 'very, very tight.'
'She said that you're our angel in the sky,' Trad recalled.
KLM told CNN the plane landed safely at Amsterdam Airport Schiphol, where an ambulance was waiting to take the man to a nearby hospital.
The man's wife said he is doing reasonably well considering the traumatic event. The hospital examined him for 12 hours and did not diagnose him with a heart attack, stroke or pulmonary embolism, she told CNN.
Trad believes this could be because of his timely treatment of the patient.
After having to cancel his Uganda trip last year because of his own heart attack, Trad said that helping save this man feels like a full circle moment for him.
He told the man it was a pleasure taking care of him and wished him the best before he ran to catch his connecting flight home.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis

Yahoo

time6 hours ago

  • Yahoo

argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis

Monica Seles - argenx 1 Monica Seles - argenx 2 Seles speaks out about her diagnosis with MG, a chronic autoimmune disease that causes muscle weakness, which can be severe and significantly impact daily life Partnership with Seles will highlight the 'Go for Greater' MG patient support initiative at the 2025 U.S. Open Tennis Championships August 12, 2025 6:45 AM EDT Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced a partnership with nine-time Grand Slam tennis champion Monica Seles. For the first time ever, Seles is publicly speaking out about her experience with myasthenia gravis (MG) in support of argenx's Go for Greater initiative. The partnership aims to raise awareness and understanding of MG, and connect those affected with available tools and support resources. 'My MG journey over the past 5 years has not been an easy one. I felt isolated and defeated as many of the activities I enjoyed were no longer physically possible for me. I've since realized that by sharing my story, I can raise awareness of this disease, empower patients to advocate for themselves and help them connect with the MG community for support,' said Monica Seles. 'I am excited to partner with the argenx team – to inspire others living with MG to rally against this disease, pursue their goals, and live a fulfilling life. We're all in this together.' 'At argenx, we are committed to supporting the MG community by fostering understanding and connection,' said Karen Massey, Chief Operating Officer, argenx. 'We applaud Monica for sharing her personal story and are excited to collaborate with her to amplify the voices of MG patients and caregivers. Her journey and dedication to this cause will help people living with MG engage in meaningful conversations and build a supportive network around this challenging disease. Together, we hope to shine a light of understanding and support for those affected by MG.' argenx has a long-standing commitment to the MG community, helping to empower patients through programs such as Go for Greater. This program supports patients in achieving a greater quality of living by fostering connections between real people with MG, and offering support and helpful resources. In addition to the new partnership with Seles, argenx is a premier Global sponsor of the upcoming 2025 U.S. Open to amplify awareness of MG on a global stage. In the U.S., over 120,000 people are living with MG, an autoimmune, neuromuscular condition that causes a variety of symptoms, including weakness in the arms and legs, fatigue, difficulty walking, and blurred and double vision. For more information about the Go for Greater campaign, visit About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, Instagram, Facebook, and YouTube. For further information, please contact: Media contact for argenx:Ben Petokbpetok@ Media contact for Real Chemistry: Ashley Cohen ascohen@ Attachments Monica Seles - argenx 1 Monica Seles - argenx 2Sign in to access your portfolio

In Real World, Women More Likely to Have Issues With GLP-1s
In Real World, Women More Likely to Have Issues With GLP-1s

Medscape

time8 hours ago

  • Medscape

In Real World, Women More Likely to Have Issues With GLP-1s

If it weren't for post hoc analyses and findings from curious academic labs, the substantial list of biological differences that separates the sexes would still be relegated to the shadows. That list — including research from the fields of neurology, cardiology, immunology, oncology, endocrinology — shows that the longtime presumption of men and women reacting as one to diagnoses, disease progression, and treatment should be considered, scientifically speaking, passé. But in the world of clinical trials, it has been and still is mostly a sexless, homogenous world. One reason: Stratifying by sex in a trial would not be cheap. 'Doing that up front would cost millions more,' said Antonella Santuccione Chadha, MD, PhD, founder and CEO of the Women's Brain Foundation and a former member of the EU Commission Directorate-General for Health and Food Safety. A significant issue is under enrollment of women in randomized trials, meaning the percentage of women enrolled isn't in line with the percentage of women with a particular disease in the real world — so signals that indicate an adverse event are not picked up. From a systems perspective, women do not clear drugs through their kidneys as quickly as men, and women maintain a higher blood concentration of the medication. 'Women may be overmedicated,' Neurologist Irving Zucker and others wrote in a 2020 analysis of 86 medications. This can lead to adverse events (AEs). And they do. ' Women experience adverse drug reactions nearly twice as often as men, yet the role of sex as a biological factor in the generation of [these reactions] is poorly understood,' Zucker wrote in that study, published in the journal Biology of Sex Differences , which showed that pharmacokinetics 'strongly linked' sex differences in adverse drug events. Antonella Santuccione Chadha, MD, PhD Among the 86 medications was the GLP-1 receptor agonist (GLP-1 RA), liraglutide. It was found to be biased toward women with regard to headache, vomiting, nausea. There are little stratified data in the GLP-1 RA receptor clinical trials, let alone appropriate enrollment percentages, as compared to real world disease prevalence. Considering that these medications are being used in patients with diabetes, obesity and overweight, cardiovascular problems, and likely in the future, to mitigate Alzheimer disease advancement, it likely would help to know how sex affects these drugs. So the question is: How can general practitioners determine what treatment is right for patients, especially their female patients, when so little evidence is based on sex? 'The side effects are very real and important to track,' said Sadiya S. Khan, MD, MSc, professor of cardiovascular epidemiology, and associate professor, medicine medical social sciences, preventive medicine, at the Feinberg School of Medicine at Northwestern University, Chicago. 'The truth about GLP-1 agonists is that you have to personalize it for the patient in front of you,' said Martha Gulati, MD, MS, professor of cardiology at Cedars-Sinai Heart Institute. Efficacy has to be balanced with the potential for side effects. 'Every individual will be slightly different.' Sex Differences of Note In its natural state, GLP-1 is found in many areas of the body, including the brain. It has multiple purposes, including gastric emptying, food intake inhibition, and neuroprotective effects on lung and cardiovascular systems. But in its natural state, GLP-1 has a short half-life, hence the pharmaceutical drive for analogues. As a class, these analogues, primarily the injectables, have been much ballyhooed for their ability to treat diabetes, induce weight loss, and reduce the risk for cardiovascular events. One recent study also demonstrated how the GLP-1 RAs can mitigate cognition issues. These analyses show how the GLP-1 RAs work at the stratified population level: In this study, women, who generally have a smaller stature than men, had higher concentrations (32%) of the tested medication than men; patients with diabetes had lower amounts of medication than those with normal blood glucose levels or prediabetes. In a new analysis of FAERS, the FDA's adverse event reporting system, among reports of neurologic related events in GLP-1 agonists, 46.25% occurred within 30 days of the start of treatment. The report, based on complaints filed from 2004 to 2025, found that 11.58% of the 250,014 listed were neurologic in nature. Women reported 65% of the 28,953 neurologic AEs events; most came from consumers. The top AEs reported were dizziness, tremor, and dysgeusia. Women who had taken semaglutide, liraglutide, and tirzepatide reported 65% of the 372 psychiatric events found in the EudraVigilance database, between January 1, 2021, and May 30, 2023. In a new JAMA article discussing the management of GLP-1 events, neurologic issues are not mentioned, just common gastrointestinal ailments, including nausea. In the huge study published in February confirming semaglutide 2.4 mg safety in overweight, obesity, cardiovascular disease but not diabetes, the sexes were segregated in listing fractures, poisoning, and procedural events but not in serious cardiac and nervous system disorders. article discussing the management of GLP-1 events, neurologic issues are not mentioned, just common gastrointestinal ailments, including nausea. In the huge study published in February confirming semaglutide 2.4 mg safety in overweight, obesity, cardiovascular disease but not diabetes, the sexes were segregated in listing fractures, poisoning, and procedural events but not in serious cardiac and nervous system disorders. The inclusion criteria for the still-running Evoke trials, which is testing oral semaglutide's efficacy in early-stage symptomatic Alzheimer's disease (AD), have no breakdown of the 1840 participants by sex, either in or the peer-reviewed summary. AD affects women significantly more than men. Efforts to reach an investigator were not successful. With regard to diabetes, it seems the sexes have more differences than commonalities, according to a 2023 study in Diabetologia , the journal of the European Association for the study of diabetes. One review found men: are younger at diagnosis; have a lower BMI and a lower risk factor burden, including hypertension and more weight gain; have a lower relative risk for cardiovascular complications and death; and get guideline recommended care more than women. Sadiya S. Khan, MD, MSc 'Across their lifetime, changes in sex hormones mean that women experience greater variations in the risk of cardiometabolic disease, including type 2 diabetes,' the Austria-based authors wrote. A Danish study reviewing more than 200,000 cases in the country's national registry reached similar conclusions. A cause for concern: Population trends show that more women are obese or severely obese, particularly among those older than 60 years. Clinical Discussion Prescribing women GLP-1 RAs takes some planning, Gulati and Khan said. Conversations about what to expect are critical, especially about potential AEs. Gulati said women respond better to these medications, especially if they are premenopausal. These physicians, both preventive cardiologists, discuss the benefits, including lower hypertension, weight reduction, and better glycemic control. Advice includes eating small meals, avoiding greasy food, and eating lots of fiber because constipation is no fun. And patients have to be prepared for the side effects. 'I have this oatmeal spiel,' Gulati said. One patient, she said, insisted on eating greasy food until the AEs won out. 'She started improving her diet and she got the results she wanted…If they get something you told them about, they know more.' Gulati, president-elect of the American Society for Preventive Cardiology, said some women won't be able to go up to the highest dosage because of the AEs. Khan said the AEs increase as the GLP-1 RA dosage increases. She said that in real life, 80% of people taking a GLP-1 RA stop because of the side effects. 'It's about going slow and seeing if people can benefit.' At least one premarketing clinical study claimed that dose adjustment by sex wasn't necessary. Robert Kushner, MD, the lead investigator on the semaglutide obesity study, said in a JAMA podcast that more than 30% of patients, at least in the phase 3 trials, stopped using semaglutide because of nausea, constipation, diarrhea, and vomiting. His advice paired with that of Khan and Gulati. Most, if not all, of this conversation could be avoided if sex-based evidence was generated in preclinical research and then used to shape the trial, said Santuccione Chadha. By investing more money in the beginning of the trial to determine sex-based differences, there would be a 'higher return on investment across the chain.' There would be fewer side effects and more adherence to drugs, the GLP-1s included. But with the current method of research, 'What happens is that there are unexpected side effects, more adverse events in the female population, who also get more serious events.' Gulati agreed more planning is needed prior to trial enrollment. 'Honestly? I think it is because of a lack of prestudy planning. Who do we want, and where will we get them?' If the trial is underpowered, 'you can't look at sex differences.' The fact that the GLP-1 RAs have proven effective in so many body systems now has more specialists prescribing these medicines. Khan said interdisciplinary care is critical, so it's necessary to have a point person. 'We are realizing this, who is owning responsibility, who is comfortable with it.'

The three key heart attack symptoms to look out for and what to do
The three key heart attack symptoms to look out for and what to do

Yahoo

time4 days ago

  • Yahoo

The three key heart attack symptoms to look out for and what to do

The NHS is urging the public to help "spread the word" about three vital signs of a heart attack. The health service has turned to social media platform X where they shared a series of images and guidance on how to respond quickly if you find yourself in such a situation. The NHS posted: "Do you know the difference between a heart attack and cardiac arrest? Know what to do in these emergencies and help spread the word." READ MORE: Parents warned over three food illnesses that can turn 'serious' quickly READ MORE: UKHSA issue urgent warning over three wet wipe brands and says 'dispose of them' Following this, the NHS outlined the steps to take if someone is suffering a cardiac arrest: "The person will be unconscious and not breathing, or not breathing normally. The faster you act, the better their chances of survival." Should you suspect someone is experiencing cardiac arrest, the guidance is to ring 999 and begin CPR immediately, reports the Mirror. The NHS also provided advice for circumstances where someone might be suffering a heart attack. They recommended: "The person will usually be conscious and may experience symptoms including chest pain, dizziness, and shortness of breath. "If you think someone is having a heart attack, call 999 immediately" Additional symptoms highlighted on the NHS website include pain in the left arm, perspiration, feeling nauseous or vomiting, and coughing or wheezing. It's also crucial to understand that someone experiencing cardiac arrest will not respond to any sound or physical contact. The NHS defines a cardiac arrest as a serious condition where the "heart stops beating in a normal way, preventing blood from pumping around the body". The NHS describes a cardiac arrest as a severe situation where the "heart stops beating in a normal way, preventing blood from pumping around the body". To address this, the NHS website offers vital advice on how to respond in these emergencies: Danger: Keep calm and check the scene is safe to approach Response: Shout 'are you alright?' and shake the person's shoulders Shout for help: Send someone for help and call 999 Airway: Tilt the head back gently to open the airway Breathing: Check for normal breathing by looking at the chest to see if it is rising and falling or listening for abnormal sounds such as infrequent and noisy gasps Compressions: If the patient is not breathing normally, start hands-only CPR pushing hard and fast in the centre of the chest Additionally, if you encounter someone suffering from a heart attack, the NHS advises adhering to a specific checklist while awaiting an ambulance: Sit the person down and make them comfortable Don't give them anything to eat or drink If available, ask them to take a 300mg aspirin tablet to chew slowly (unless they are under 16 or allergic) Moreover, if you come across someone having a heart attack, the NHS recommends following a particular checklist while waiting for an ambulance:. For more information on suitable actions or symptoms to look out for, refer to the NHS website.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store